Bioactivity and immunological evaluation of LPS from different serotypes of Helicobacter pylori
,
Abstract
Background and Objectives: Helicobacter pylori is the causative agent of peptic ulcer disease and a co-factor in development of gastric malignancies. LPS are among toxic substances produced by H. pylori exhibiting low endotoxic activity compared to typical bacterial LPS. The aim of this study was to investigate bioactivity of LPS produced by different serotypes of Helicobacter pylori compared to Escherichia coli and Brucella abortus LPS.
Materials and Methods: Bacterial LPS was extracted by the hot phenol-water method. Biological activities of LPS were determined via the limulus lysate assay, pyrogenic assay, and blood pressure and PBMC induction test in rabbits.
Results: Biological activity of O serotype LPS of H. pylori was less than the biological activity of other H. pylori serotypes.
Conclusion: Our data supported the hypothesis that the unique bacterial LPS of the O formulation of a multivalent H. pylori vaccine.
Kawahara T, Teshima S , Kuwano Y, Oka A, Kishi K, Rokutan K. Helicobacter pylori lipopolysaccharide induces apoptosis of cultured guinea pig gastric mucosal cells. Am J Physiol Gastrointestinal Liver Physiol 2001;281: 726-734.2. Fujimoto Y, Iwata M, Imakita N, Shimoyama A, Suda Y, Kusumoto S, et al. Synthesis of immuno regulatory Helicobacter pylori lipopolysaccharide partial struc- tures. Tetrahedron Lett 2007; 48: 6577-6581.
Hynes SO, Ferris JA , Szponar B, Wadstrom T, Fox JG , O’Rourke J, Larsson L, et al. Comparative chemical and biological characterization of the lipopolysaccharides of gastric and enterohepatic Helicobacter. Helicobacter 2004; 9: 313-23.
Nielsen H, Birkholz S, Andersen LP, Moran APJ.Neutrophil activation by Helicobacter pylori polysaccharides. Infect Dis 1994; 170: 135-139.
Pérez-Pérez GI, Shepherd VL , Morrow JD, Blaser MJ. Activation of human Th1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun 1995; 63: 1183-1187.
Yokota S, Saito H, Kubota T, Yokosawa N, Amano K, Fuji N. Measles virus suppresses interferon-α signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-α receptor complex. Virology 2003; 306: 135-146.
Lepper PM, Triantafilou M, Schumann C, Schneider EM,Triantafilou K. Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4. Cell Microbiol 2005; 7: 519-528.
Yukari F, Masato I, Noriko I, Synthesis of immune- regulatory H. pylori LPS partial structures. Tetrahedron Letters 2007; 48 : 6577-6581.
Suda Y, Kim YM, Ogawa T, Yasui N. Chemical structure and biological activity of a lipid A component from H. pylori strain 206. J Endotoxin Res 2001; 7: 95-104.
Ogawa T, Asai Y, Sakai Y, Oikawa M. Endotoxic and immmuno-biological activities as a chemically synthesized lipidA of H. pylori strain 206-1. FEMS Immunol Med Microbiol 2003; 36: 1-7.
Matsuyama N, Kirikae T, Kirikae F, Hashimoto M, Amanot K, Hayashi S, et al. Non-standard biological activities of lipopolysaccharide from Helicobacter pylori. J Med Microbiol 2001; 50: 865-869.
Peek JR, Blaser MJ. H. pylori and gasterointestinal tract adeno carcinomas. Nat Rev Cancer 2002; 2: 28-37.
Muotiala AIM, Helander L, Pyhala TU, Moran AP. Low biological activity of H. pylori LPS. Infect Immun 1992;60: 1714-1716.
Ogawa T, Suda Y, Kashihara W, Hayashi T, Kusmoto S, Tamura T. Immuno-biological activities of chemically defined lipid A and E. coli – type synthetic lipid A (compound 506). Vaccine 1997; 15: 1598-1605.
Ootsubo CT, Okumura N, Takashi H, Wakebe K, Imagawa M. H. pylori LPS inhibits acid secretion in pylorus -ligated conscious rats. Biochem Biophys Res Comun 1997; 236: 532-537.
Padol IT, Moran AP, Hunt RH. Effect of purified LPS from strains of H. pylori and H. felis on acid secretion in mouse gastric glands in vitro. Infect Immun 2001;3891-3896.
Britton SE, Papp-Szabo J, Simala-Grant L, Morrison DE, Taylor M. A novel Helicobacter pylori cell-surface polysaccharide. Carbohydr Res 2005; 340: 1605-1611.
Luo YH, Yan J, Mao YF. Helicobacter pylori lipopo- lysaccharide: Biological activities in vitro and in vivo, pathological correlation to human chronic gastritis and peptic ulcer. World J Gastroenterol 2004; 10:2055-2059.
Weltzin R, Guy B, Thomas JWD, Gianasca PJ, Monath TP. Parenteral adjuvant activities of E. coli heat-labile toxin and its B subunit for immunization of mice against gastric H. pylori infection. Infect Immun 2000; 68:2775-2782.
Innocent M, Thoreson AC, Ferrero RL, Stromberg E, Bolin I, Eriksson L, Svennerholm AM, et al. Helicobacter pylori-induced activation of human endothelial cells. Infect Immun 2002; 70: 4581-4590.
Wesphal O, Jann K. Bacterial LPS; extraction with phenol water and further applications of the procedure. Methods Carbohydr Chem 1965; 5: 83-91.
Appelmelk BJ, Shiberu B, Trinks C. Phase Variation in Helicobacter pylori Lipopolysaccharide. Infect Immun 1998; 66: 70-76.
Taylor JM, Ziman ME, Huff JL, Morosoki NM, Vajdy M. H. pylori LPS promotes a Th1 type immune response in immunized mice. Vaccine 2006; 24: 4987-4994.
24. Lammli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
Tsai CM, Frasch CEA. Sensitive silver stain for detecting LPS in polyacryl amide gels. Anal Biochem 1982; 119:115-119.
Goldstein J, Hoffiman T, Frasch C, Lizzio EF, Beining, PR, Hochstein D. Lipopolysaccharide (LPS) from B. abortus is less toxic than from E. coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccine. Infect Immun 1992; 60: 1385-1389.
Moran AP. Lipopolysaccharide in bacterial chronic infection: insights from Helicobacter pylori lipopo- lysaccharide and lipid A. Int J Med Microbiol 2007;297: 307-319.
Venter P, Lues JF. Extraction methods for LPS from E. coli ATCC 25922 for quantitative analysis by capillary electrophoresis. Int J Food Microbiol 2003; 84:245-250.
Zherebylo OIe, Moroz SM, Hvozdiak RI. Characteristics of bacterial LPS depending on extraction method. Ukr Biokhim Zh 2000: 72, 51-55.
Salgado F, Garcia A, Onate A, Gonzalez C, Kawaguchi F. Increased in vitro and in vivo biological activity of LPS extracted from clinical low virulence vacA genotype H. pylori strains. J Med Microbiol 2002; 51:771-776.
Giudice DG, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines 2009; 8: 1037-1049.
| Files | ||
| Issue | Vol 5 No 2 (2013) | |
| Section | Articles | |
| Keywords | ||
| Bioactivity H. pylori LPS | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
